Life Therapeutics Limited

ASX:LFE ISIN:AU000000LFE1

Feb 10, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Life Therapeutics Limited Company Summary

Life Therapeutics is an international company that specializes in niche therapeutic hyperimmune products. It has 14 operational plasma collection centers and signed leases for a further 2 centers around the US. The Company has considerable experience recruiting and collecting hard to find hyperimmune plasma for IND studies and clinical trials. Life Therapeutics has 500 employees, located in the United States and 14 plasma donor centers in eight American States. It has an established U.S. American Depositary Receipt (ADR) Level I program, which enables trading in Life Therapeutics shares by U.S. based investors. The company's divisions are all headquartered in Atlanta, Georgia.

COMPANY DATA

	Fax	(02) 8977 9099

	Principal Sector	Health & Pharm

	Principal Industry	Biotechnology

	Listed	1986/05/08

	Homepage	www.life-therapeutics.com

Key Developments: Life Therapeutics Limited

	Life Therapeutics to Appoint Independent Expert to Value Kedrion Transaction AUG 17, 2007 11:06 - Article Views: 1,283 Life Therapeutics (ASX: LFE) today announced that the company has resolved to appoint an Independent Expert to provide an independent valuation on the proposed transaction with Kedrion S.p.A ("Kedrion"), pursuant to the terms announced on 30 July 2007. This will include an assessment of the value of LFE's equity stake in Kedrion.

	Life Therapeutics to Deliver on Vertical Integration Strategy Through Partnership with Leading Fractionator JUNE 25, 2007 10:21 - Article Views: 1,900 Life Therapeutics (ASX: LFE) today provided details of an agreement (the "Agreement") with Kedrion S.p.A ("Kedrion"), a leading European speciality pharmaceutical company and Italy's largest fractionator, that will enable the company to deliver on its strategy to become a vertically integrated operator. Under the terms of the Agreement, Life Therapeutics will take up a 5.5% equity stake in Kedrion and will divest assets from its Life Sera business into a new joint venture company with Kedrion ("Newco").

	Life Therapeutics Update on Status of Heads of Agreement with European Fractionator MAY 31, 2007 09:19 - Article Views: 1,248 On 19 March 2007 Life Therapeutics (ASX: LFE) (PNK: LFEFY) announced that it had entered into a non-binding Heads of Agreement with a European fractionator in relation to a proposed transaction. At that time, the company granted to the European fractionator exclusive negotiation rights up until 1 June 2007.

	Life Therapeutics Signs New Two Year Contract Valued up to A$12M per year OCT 24, 2006 21:05 - Article Views: 1,396 Life Therapeutics (ASX: LFE)(PNK: LFEFY) has signed a new two year contract to produce hyperimmune plasma for a major fractionator. The value of the contract ranges from a minimum of A$4M up to A$12M per year for two years.

	Life Therapeutics Rolls Out Donor Computer System To Collection Centers On The West Coast of USA OCT 15, 2006 11:56 - Article Views: 1,539 Donor Computer System now rolled out to all Collection Centers ATLANTA - 11 October, 2006 - Life Therapeutics (ASX: LFE) has now successfully completed the computerisation of the 5 West Coast plasma collection centres.

	Life Therapeutics Paves Their Way to a NASDAQ Listing With Sale of Sydney Property SEP 12, 2006 12:04 - Article Views: 2,295 Life Therapeutics (ASX: LFE)(PNK: LFEFY) announced today that it has completed the sale of the Frenchs Forest building for A$9.25m to a fund controlled by MacarthurCook Ltd (ASX: MCK).

	Life Therapeutics to Provide Anti-Anthrax Plasma SEP 6, 2006 11:48 - Article Views: 942 Life Therapeutics (ASX: LFE) will supply Cangene Corporation with Anti-Anthrax plasma for Cangene to produce an Anti-Anthrax hyperimmune for the U.S. Department of Health and Human Services.

	Life Therapeutics Opens Two New US Plasma Collection Centers JULY 26, 2006 16:36 - Article Views: 1,021 Life Therapeutics (ASX: LFE) announced today that it has signed leases to open two new donor collection centers: one in Sacramento and the second in Long Beach in California. It is expected that these centers will become operational at the end of August 2006.

	Life Therapeutics Generates A$3.5m Free Cash On Sale of Frenchs Forest Building JULY 18, 2006 00:27 - Article Views: 2,465 Life Therapeutics (ASX: LFE) announced today that it has exchanged contracts with MacarthurCook Ltd (ASX: MCK) for the sale of its Frenchs Forest building.

	Life Therapeutics Granted US$1 Million to Develop Anti-Cancer Drug JUNE 21, 2006 12:03 - Article Views: 1,079 GammaCan International (OTCBB: GCAN), and Life Therapeutics (ASX: LFE) today announced a joint effort to develop VitiGam, an innovative anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease, in connection with a grant to be provided by the BIRD Foundation.